Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …

Background: The objective of the FLIGHT3 study was to evaluate the long-term safety and
efficacy of indacaterol/glycopyrrolate*(IND/GLY) versus an active comparator, IND, in …

Background Indacaterol/glycopyrronium (IND/GLY) is approved for maintenance treatment
of adult patients with COPD. This post hoc analysis explored the efficacy and safety of …

Background and objective Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (qd)
has demonstrated greater improvements in lung function, patient‐reported outcomes and …

In this pooled analysis, we compared the effect of indacaterol/glycopyrronium (IND/GLY) by
sex versus other commonly used chronic obstructive pulmonary disease (COPD) treatments …

Background and aim Long-acting bronchodilators are the preferred option for maintenance
therapy of patients with chronic obstructive pulmonary disease (COPD). The aim of this …

Background Dual bronchodilation combining a long-acting β 2-agonist (LABA) and a long-
acting muscarinic antagonist (LAMA) is the preferred choice of treatment recommended by …

Purpose COPD is a progressive disease characterized by exacerbations and a decline in
health status and lung function. Clinically important deterioration (CID) is a composite …

BACKGROUND: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for
the treatment of COPD. METHODS: This 12-week randomised, parallel-group study …

Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …